Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia
Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia
复制标题
DOI：
10.1111/jcpt.12251
复制
发表时间：
2015-06
影响因子：
2
通讯作者：
C. Zhang;X-H Chen;J. Liu;L. Gao;Y. Liu;P. Kong;X. Zhang
中科院分区：
文献类型：
--
作者：
C. Zhang;X-H Chen;J. Liu;L. Gao;Y. Liu;P. Kong;X. Zhang
Chemotherapy can increase treatment‐related mortality associated with future haematopoietic stem cell transplantation (HSCT) for patients with relapsed/refractory acute myeloid leukaemia (AML). There is usually insufficient time to find a suitable unrelated donor for these patients. We report on the use of decitabine, a DNA methyltransferase inhibitor as a conditioning regimen for a patient undergoing HSCT.
